JY
GLMD icon

Jeff Yass’s Galmed Pharmaceuticals GLMD Stock Holding History

Jeff Yass’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7
Closed -$16K – 13265
2022
Q1 		$16K Sell
7
-154
-96% -$349K ﹤0.01% 12679
2021
Q4 		$422K Buy
161
+41
+34% +$148K ﹤0.01% 9615
2021
Q3 		$482K Buy
120
+80
+200% +$336K ﹤0.01% 9483
2021
Q2 		$174K Buy
+40
New +$174K ﹤0.01% 11732
2019
Q3 		– Sell
-7
Closed -$74K – 10399
2019
Q2 		$74K Sell
7
-2
-22% -$20.6K ﹤0.01% 9726
2019
Q1 		$111K Buy
9
+1
+13% +$11.6K ﹤0.01% 8204
2018
Q4 		$81K Hold
8
– – ﹤0.01% 8308
2018
Q3 		$160K Buy
+8
New +$150K ﹤0.01% 8374

Other funds holding GLMD

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $334M AUM 26.48% 1-Year Est. Return

Jeff Yass's GLMD Position: Q3 2024 in Review

Jeff Yass sold out of Galmed Pharmaceuticals (GLMD) in Q3 2024, closing a stake of 121 shares — an estimated $3.33K sold.

Jeff Yass first reported a position in GLMD in Q4 2016 and held it in 16 quarters. The position peaked at $244K in Q4 2021. 7 funds tracked by Wall St. Rank hold GLMD as of Q3 2024.

  • Jeff Yass reported no remaining Galmed Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Jeff Yass sold 121 Galmed Pharmaceuticals shares in Q3 2024, an estimated $3.33K.
  • Jeff Yass first reported a position in Galmed Pharmaceuticals in Q4 2016 and held it in 16 quarters.
  • Jeff Yass's Galmed Pharmaceuticals position peaked at $244K in Q4 2021.
  • 7 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2024.

Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.